Rheumatoid Arthritis Completed Phase 3 Trials for Baricitinib (DB11817)

Also known as: Rheumatoid Arthritis(RA) / Rheumatoid Arthritis, NOS / Rheumatoid Arthritis RA / Rhematoid Arthritis / Rheumatic Arthritis / Rheumatoid Arthritis (RA) / Arthritis, Rheumatoid / Arthritis,Rheumatoid / Arthritis, Rheumatoid (RA) / Rheumatoid Arthritis(RA) / RA / Systemic rheumatoid arthritis / Rheumatoid arthritis (disorder) / Arthritis rheumatoid / Rheumatoid arthritis, unspecified / R arthritis / Rh arthritis / Rheumatoid arthritis NOS / Rheumatoid arthritis NOS (disorder)

IndicationStatusPhase
DBCOND0027961 (Rheumatoid Arthritis)Completed3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01721044A Moderate to Severe Rheumatoid Arthritis StudyTreatment
NCT01710358A Study in Moderate to Severe Rheumatoid ArthritisTreatment
NCT01711359A Study in Participants With Moderate to Severe Rheumatoid ArthritisTreatment
NCT01721057A Study in Moderate to Severe Rheumatoid Arthritis ParticipantsTreatment
NCT02265705A Study of Baricitinib (LY3009104) in Participants With Rheumatoid Arthritis (RA)Treatment